On September 15, 2020, Demoday was held as a part of the Biomedtech track of «Moscow Accelerator». The jury and experts of the acceleration program of the Moscow Government’s Innovation Agency evaluated 18 innovative projects, among which a technology that allows to predict and avoid risks of adverse drug reactions – «PharmacoGenomeX2».
Alla Panchenko, CBDO of PGX2 pitched the startup, mentioning current issues, technology highlights, market and business model insights.
Invitro, the largest private company on the commercial laboratory research market in Russia, invited PGX2 to launch a pilot project with a network of laboratories. PGX2 startup team also received the right to participate in the final of the Biobridge international acceleration program in Austria in 2021.
The PGX2 team thanks the organizers and partners for a quick and intense acceleration.
The Moscow accelerator is a joint initiative of the Moscow innovation Agency and the Moscow Innovation Cluster Foundation, implemented with the support of the Moscow Department of Entrepreneurship and Innovative development.
The partners of the BioMedTech track of the acceleration program are the HIMRAR group of companies and the Invitro holding.
The cluster's priorities are aimed at supporting and implementing projects in the field of creating innovative medicines, medical diagnostic and therapeutic products, new biocompatible materials and cell technology products. Special emphasis is placed on personalized and translational medicine, biomarkers, bioinformatics, as well as devices for diagnostics and monitoring of the state of physiological parameters.